These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia. Dogra R; Bhatia R; Shankar R; Bansal P; Rawal RK Anticancer Agents Med Chem; 2018; 18(14):1936-1951. PubMed ID: 30360730 [TBL] [Abstract][Full Text] [Related]
5. Molecular remission and response patterns in patients with mutant- Stein EM; DiNardo CD; Fathi AT; Pollyea DA; Stone RM; Altman JK; Roboz GJ; Patel MR; Collins R; Flinn IW; Sekeres MA; Stein AS; Kantarjian HM; Levine RL; Vyas P; MacBeth KJ; Tosolini A; VanOostendorp J; Xu Q; Gupta I; Lila T; Risueno A; Yen KE; Wu B; Attar EC; Tallman MS; de Botton S Blood; 2019 Feb; 133(7):676-687. PubMed ID: 30510081 [TBL] [Abstract][Full Text] [Related]
6. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Amatangelo MD; Quek L; Shih A; Stein EM; Roshal M; David MD; Marteyn B; Farnoud NR; de Botton S; Bernard OA; Wu B; Yen KE; Tallman MS; Papaemmanuil E; Penard-Lacronique V; Thakurta A; Vyas P; Levine RL Blood; 2017 Aug; 130(6):732-741. PubMed ID: 28588019 [TBL] [Abstract][Full Text] [Related]
7. Enasidenib and ivosidenib in AML. Martelli MP; Martino G; Cardinali V; Falini B; Martinelli G; Cerchione C Minerva Med; 2020 Oct; 111(5):411-426. PubMed ID: 32955829 [TBL] [Abstract][Full Text] [Related]
8. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells. Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760 [TBL] [Abstract][Full Text] [Related]
9. Targeting the Amaya ML; Pollyea DA Clin Cancer Res; 2018 Oct; 24(20):4931-4936. PubMed ID: 29769206 [TBL] [Abstract][Full Text] [Related]
10. Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation. DiNardo C Clin Adv Hematol Oncol; 2018 Apr; 16(4):247-249. PubMed ID: 29742078 [No Abstract] [Full Text] [Related]
11. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987 [TBL] [Abstract][Full Text] [Related]
12. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study. Fathi AT; DiNardo CD; Kline I; Kenvin L; Gupta I; Attar EC; Stein EM; de Botton S; JAMA Oncol; 2018 Aug; 4(8):1106-1110. PubMed ID: 29346478 [TBL] [Abstract][Full Text] [Related]
13. Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. de Botton S; Brandwein JM; Wei AH; Pigneux A; Quesnel B; Thomas X; Legrand O; Recher C; Chantepie S; Hunault-Berger M; Boissel N; Nehme SA; Frattini MG; Tosolini A; Marion-Gallois R; Wang JJ; Cameron C; Siddiqui M; Hutton B; Milkovich G; Stein EM Cancer Med; 2021 Sep; 10(18):6336-6343. PubMed ID: 34427990 [TBL] [Abstract][Full Text] [Related]
14. Enasidenib. Krämer A; Bochtler T Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631 [TBL] [Abstract][Full Text] [Related]
16. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972 [TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729 [TBL] [Abstract][Full Text] [Related]
19. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Stein EM; Fathi AT; DiNardo CD; Pollyea DA; Roboz GJ; Collins R; Sekeres MA; Stone RM; Attar EC; Frattini MG; Tosolini A; Xu Q; See WL; MacBeth KJ; de Botton S; Tallman MS; Kantarjian HM Lancet Haematol; 2020 Apr; 7(4):e309-e319. PubMed ID: 32145771 [TBL] [Abstract][Full Text] [Related]
20. Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. Stein EM Future Oncol; 2018 Jan; 14(1):23-40. PubMed ID: 29243965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]